Skip to main content
Pharmaceutical Methods logoLink to Pharmaceutical Methods
. 2012 Jul-Dec;3(2):57–61. doi: 10.4103/2229-4708.103873

RP-UPLC method development and validation for the simultaneous estimation of ibuprofen and famotidine in pharmaceutical dosage form

Yarram Ramakoti Reddy 1,, Kakumani Kishore Kumar 1, MRP Reddy 1, K Mukkanti 1
PMCID: PMC3658083  PMID: 23781479

Abstract

Aim and Backrgound:

A stability-indicating LC method was developed for the simultaneous determination of Ibuprofen and Famotidine in pharmaceutical dosage forms.

Materials and Methods:

The chromatographic separation was achieved on Acquity UPLC BEH C-18,50 mm × 2.1 mm and 1.7 μm column with gradient elution. The mobile phase A contains a mixture of 50 mM sodium acetate buffer (pH 5.5): methanol (85:15, v/v), and the mobile phase B contains a mixture of 50 mM sodium acetate buffer (pH 5.5): methanol (25:75, v/v). The flow rate was 0.3 mL min-1, and the detection wavelength was 260 nm.

Results:

The limit of detection for Ibuprofen and Famotidine was 1.6 and 1.2 μg mL-1, respectively. The limit of quantification (LOQ) for Ibuprofen and Famotidine was 5.1 and 4.3 μg mL-1, respectively.

Conclusion:

This method was validated for accuracy, precision, and linearity. The method was also found to be stability indicating.

Keywords: Famotidine, ibuprofen, ssimultaneous, sstability-indicating, UPLC

INTRODUCTION

Famotidine (FM), 3-(((2-((aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N’-(aminosulfonyl) propanimidamide is a potent, competitive, and reversible inhibitor of histamine action at the H2 receptor. It is used for the treatment of duodenal and gastric ulcers. The empirical formula of Famotidine is C8H15N7O2S3 and its molecular weight is 337.43. Famotidine is available in 20 mg and 40 mg for oral administration.[1]

Ibuprofen (IB) ((2RS)-2-[4-(2-Methylpropyl)phenyl]propanoic acid) is a non-steroidal anti-inflammatory drug, which is available in 400 mg, 600 mg, and 800 mg tablets for oral administration. It is indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis for relief of mild to moderate pain and also indicated for the treatment of primary dysmenorrhea. The empirical formula for Ibuprofen is C13H18O2 and its molecular weight is 206.29.[2]

To the best of our knowledge, few liquid chromatography procedures were described for the individual determination of Ibuprofen [Figure 1a] and Famotidine [Figure 1b].[217] These procedures were developed to estimate either Ibuprofen or Famotidine individually and from formulation or plasma, whereas no single method has been reported for their simultaneous estimation from the formulation. Hence, it is necessary to develop a stability indicating, rapid, accurate, and validated LC method for the simultaneous determination of Ibuprofen and Famotidine from combined dosage form for generic drug development.

Figure 1.

Figure 1

Chemical structure and chemical name of (a) Ibuprofen (b) Famotidine.

Ultra performance liquid chromatography (UPLC) is a recent technique in liquid chromatography, which enables significant reductions in separation time and solvent consumption. Literature indicates that UPLC system allows about 9-fold decreases in analysis time as compared to the conventional HPLC system using 5 μm particle size analytical columns, and about 3-fold decrease in analysis time in comparison with 3 μm particle size analytical columns without compromise on overall separation.

EXPERIMENTAL

Apparatus

Acquity UPLCTM system (Waters, Milford, USA) used consisting of a binary solvent manager, a sample manager and a UV detector. The output signal was monitored and processed using empower software, water bath equipped with MV controller (Julabo, Seelbach, Germany) was used for hydrolysis studies. Photo stability studies were carried out in a photo stability chamber (Sanyo, Leicestershire, UK). Thermal stability studies were performed in a dry air oven (MACK Pharmatech, Hyderabad, India).

Reagents and chemicals

Ibuprofen and Famotidine (Duexis) tablets (800 mg of Ibuprofen and 26 mg of Famotidine) were purchased from the pharmacy. Sodium acetate trihydrate, triethylamine, glacial acetic acid, methanol for HPLC were purchased from Merck, Darmstadt, Germany, and water used was obtained by using Millipore MilliQ Plus water purification system

Chromatographic conditions

The chromatographic column used Acquity UPLC BEH C-18,50 mm × 2.1 mm and 1.7 μm particle size. The separation was achieved on a gradient method. The buffer used for mobile phase and diluent was 0.05 M sodium acetate buffer and 2 ml of triethyl amine in 1000 ml of water and adjusted the pH to 5.5 with glacial acetic acid. Mobile phase A was a mixture of pH 5.5 buffer and methanol in the ratio of 85: 15(v/v), respectively, and the mobile phase B contains a mixture of pH 5.5 buffer and methanol in the ratio of 75:25 (v/v), respectively. The flow rate of mobile phase was set as 0.3 Ml min-1. The UPLC gradient program was set as: Time (min)/% solution B: 0.01/10,1.6/100, 2.8/100, 3.0/10, and 3.5/10. The column temperature was maintained at 25°C, and the detector was monitored at a wavelength 260 nm. The injection volume was 1.5 μL.

Preparation of stock solutions

A standard solution containing 1600 μg/ml of IBU and 50 μg/ml of FAM were prepared by dissolving IB and FM in diluent (50:50 (v/v) pH 5.5 sodium acetate buffer and methanol).

Preparation of sample solution

Twenty tablets, each containing 800 mg of IB and 26 mg of FM, were weighed individually to determine the average weight and powdered separately in a mortar. A quantity of powder equivalent to 52 mg of FM and 1600 mg of IB were weighed and transferred into a 500 ml volumetric flask, added 300 ml of diluent and sonicated for 45 minutes with intermediate shaking and then made up to volume with diluent.

RESULTS AND DISCUSSION

Method development and optimization of stability indicating assay method

The method was optimized to separate major degradation products formed under varies stress conditions. I (pKa = 4.4) is acetic compound, whereas FM (pKa = 7.1) is basic compound. The main target of the chromatographic method is to get the separation for closely eluting degradation products. The degradation samples were run using different stationary phases like C18, C8, Cyano, and mobile phases containing buffers like phosphate, sulfate, and acetate with different pH (2-7) and using organic modifiers like acetonitrile and methanol in the mobile phase. But, the separation was satisfactory in the adopted chromatographic conditions only [Table 1 and Figure 2] the optimized conditions are, the mobile phase A was a mixture of pH 5.5 buffer and methanol in the ratio of 85:15(v/v), respectively, and the mobile phase B contains a mixture of pH 5.5 buffer and methanol in the ratio of 75:25 (v/v), respectively.

Table 1.

Results from system suitability test

graphic file with name PMeth-3-57-g002.jpg

Figure 2.

Figure 2

A typical HPLC chromatogram of Famotidine and Ibuprofen from tables.

Specificity – forced degradation studies

Forced degradation studies were performed on IB and FM to prove the stability-indicating property of the method. The stress conditions employed for degradation study of FM and IB include light exposure, heat (100°C), acid hydrolysis (1 N HCl), base hydrolysis (1 N NaOH), water hydrolysis, and oxidation (3% H2O2). For light studies, the monitoring period was 10 days, whereas for heat, acid, base, and water hydrolysis, it was 24 h. Oxidation was carried out for 2 h. Peak purity of the principal peak in the chromatogram of stressed samples of IB and FM tablets was checked using photo diode array detector.

Degradation was not observed in IB and FM stressed samples that were subjected to light and water hydrolysis. However, the degradation was observed under heat, oxidative conditions, base hydrolysis, and acid hydrolysis. The peak purity test results derived from PDA (Photo Diode Array detector) confirmed that the IB and FM peaks were pure and homogeneous in all the analyzed stress [Table 2]. This indicates that the method is specific and stability indicating.

Table 2.

Summary of results from forced degradation experiments

graphic file with name PMeth-3-57-g004.jpg

Validation

Method validation was performed as per ICH guidance for simultaneous determination of IB and FM in the formulations. The following validation characteristics were addressed, linearity, detection limit, quantification limit, precision, accuracy, robustness, ruggedness, and specificity.[1820]

Precision

The precision of an analytical method gives information on the random error. It expresses of agreement between a series of measurements obtained from multiple sampling of the same homogeneous sample under prescribed conditions. The percentage RSD values for the precision study was 0.5%, 0.6% (inter-day precision) and 0.5%, 0.6% (intra-day precision) for IB and FM, respectively. This is confirming good precision of the method. The results are summarized in Table 3.

Table 3.

Results from determination of intermediate precision

graphic file with name PMeth-3-57-g005.jpg

Accuracy

The accuracy of an analytical method expresses the nearness between the reference value and found value. The accuracy of the method was evaluated in triplicate at three concentration levels, i.e. 50%, 100%, and 150% of target test concentration (52 μg mL–1 of FM, 1600& μg mL–1) of IBU in tablets. The results obtained are shown in Table 4.

Table 4.

Results from study of accuracy for drug product

graphic file with name PMeth-3-57-g006.jpg

Limit of detection (LOD) and limit of quantification (LOQ)

The LOD and LOQ were estimated at a signal-to-noise ratio of 3:1 and 10:1, respectively, by injecting a series of dilute solutions with known concentration. The limit of detection of IB and FM was 1.72 and 0.54 μg mL-1, respectively. The limit of quantification of IB and FM was 5.73 and 1.64 μg mL-1, respectively.

Linearity

The calibration curves plotted for FM and IB were linear over the concentration range of 50-160 μg/ml for FM, 1600-4800 μg/ml for IB. Peak areas were plotted against concentrations, and linearity regression analysis performed for the resultant curve. The correlation coefficient values of FM and IB are 1.000 and 0.999.

Robustness

The robustness of a method is its capacity to remain unaffected by small changes in conditions. To determine the robustness of the method, the experimental conditions were deliberately altered and system suitability parameters like relative standard deviation for replicate injections of IB and FM peaks and the USP resolution factor between IB and FM peaks were evaluated. The mobile phase flow rate was 0.3 mL min–1. This was changed by 0.03 units to 0.27 and 0.33 mL min–1, and the effect was studied. Similarly, the effect of column temperature was studied at 20 and 30 °C instead of 25 °C. The effect of mobile phase organic composition was studied by ± 10%. The effect of mobile phase pH was studied by ± 0.2 units.

In all the deliberate varied chromatographic conditions (flow rate, column temperature, and composition of organic solvent), no significant difference observed in system suitability [Table 5].

Table 5.

Results from study of robustness

graphic file with name PMeth-3-57-g007.jpg

CONCLUSION

A novel UPLC method proves to be simple, linear, precise, accurate, robust, rugged, and specific. The total runtime was 4 min, within which two drugs and their degradation products were separated. The method was completely validated showing satisfactory data for all the method validation parameters tested. The developed method is stability-indicating and can be used for simultaneous quantitative determination of the drugs IB and FM in presence of degradation products in stability by the industry. The adopted UPLC method can also be useful for the assay estimation of IB tablets, FM tablets individually also.

Footnotes

Source of Support: Nil

Conflict of Interest: None declared.

REFERENCES

  • 1. [Last Accessed on 2012 April 9]. Available from: http://www.rxlist.com/ibuprofen-drug.htm .
  • 2. [Last Accessed on 2012 April 9]. Available from: http://www.rxlist.com/pepcid-drug.htm .
  • 3.Carlucci G, Biordi L, Napolitano N, Bologna M. Determination of famotidine in plasma, urine and gastric juice by high-performance liquid chromatography using disposable solid-phase extraction columns. J Pharm Biomed Anal. 1988;5:515–9. doi: 10.1016/0731-7085(88)80019-0. [DOI] [PubMed] [Google Scholar]
  • 4.Dowling TC, Frye RF. Determination of famotidine in human plasma and urine by high-performance liquid chromatography. J Chromatogr B. 1999;732:239–43. doi: 10.1016/s0378-4347(99)00269-8. [DOI] [PubMed] [Google Scholar]
  • 5.Sajid Husain, Sara Khalid, Nagaraju V, Rao Nageswara R. High-performance liquid chromatographic separation and determination of small amounts of process impurities of famotidine in bulk drugs and formulations. J Chromatogr A. 1996;743:328–34. [Google Scholar]
  • 6.Helali N, Tran NT, Monser L, Taverna M. Capillary zone electrophoresis method for the determination of famotidine and related impurities in pharmaceuticals. Talanta. 2008;74:694–8. doi: 10.1016/j.talanta.2007.06.036. [DOI] [PubMed] [Google Scholar]
  • 7.Wanwimolruk S, Zoest AR, Wanwimolruk SZ, Hung CT. Sensitive high-performance liquid chromatographic determination of famotidine in plasma: Application to pharmacokinetic study. J Chromatogr A. 1991;572:227–38. doi: 10.1016/0378-4347(91)80487-w. [DOI] [PubMed] [Google Scholar]
  • 8.Agrawal YK, Shivramchandra K, Singh GN, Rao BE. Spectrophotometric determination of famotidine in pharmaceutical preparations. J Pharm Biomed Anal. 1992;10:521–3. doi: 10.1016/0731-7085(92)80074-w. [DOI] [PubMed] [Google Scholar]
  • 9.Ali Z, Zuhri Abu, Shubietah Raqi M, Badah Ghassan M. Extractional-spectrophotometric determination of famotidine in pharmaceutical formulations. J Pharm Biomed Anal. 1999;21:459–65. doi: 10.1016/s0731-7085(99)00139-9. [DOI] [PubMed] [Google Scholar]
  • 10.Rahman Asirur, Hoffman Norman E. High-performance liquid chromatographic determination of famotidine in urine. J Chromatogr B. 1988;428:395–401. doi: 10.1016/s0378-4347(00)83934-1. [DOI] [PubMed] [Google Scholar]
  • 11.Carlucci G, Mazzeo P, Vetuschi C, Di Giuseppe E. Reversed-phase high-performance liquid chromatographic and derivative UV spectrophotometric determination of famotidine in pharmaceutical preparations. Int J Pharmaceutics. 1994;102:271–4. [Google Scholar]
  • 12.Beaulieu N, Graham SJ, Sears RW, Lovering EG. Validation of a method for the assay of related compounds in famotidine raw materials and formulations Original Research Article. J Pharm Biomed Anal. 1989;7:1705–9. doi: 10.1016/0731-7085(89)80184-0. [DOI] [PubMed] [Google Scholar]
  • 13.The United state pharmacopoeial Convention 12601, Rockville. 31st ed. MD, USA: 2008. United state pharmacopoeia; pp. 2372–4. [Google Scholar]
  • 14.Rao DD, Rao PV, Sait SS, Mukkanti K, Chakole D. Simultaneous Determination of Ibuprofen and diphenhydramine Citrate in Tablets by Validated LC. Chromatographia. 2009;69:1133–6. [Google Scholar]
  • 15.Farrar H, Letzig L, Gill M. Validation of a liquid chromatographic method for the determination of ibuprofen in human plasma. J Chromatogr B. 2002;780:341–8. doi: 10.1016/s1570-0232(02)00543-3. [DOI] [PubMed] [Google Scholar]
  • 16.Whelan MR, Ford JL, Powell MW. Simultaneous determination of ibuprofen and hydroxypropylmethylcellulose (HPMC) using HPLC and evaporative light scattering detection. J Pharm Biomed Anal. 2002;30:1355–9. doi: 10.1016/s0731-7085(02)00394-1. [DOI] [PubMed] [Google Scholar]
  • 17.Sochor J, Klims J, Sedlacek J, Zahradnicek M. Determination of ibuprofen in erythrocytes and plasma by high performance liquid chromatography. J Pharm Biomed Anal. 1995;13:899–903. doi: 10.1016/0731-7085(95)01306-6. [DOI] [PubMed] [Google Scholar]
  • 18.Geneva: IFPMA; 1996. International Conference on Harmonization. Text on Validation of Analytical Procedures: Term and definition Q2A, International Conference on Harmonization. [Google Scholar]
  • 19.Geneva: IFPMA; 1997. International Conference on Harmonization. Validation of Analytical Procedures: Methodology Q2B, International Conference on Harmonization. [Google Scholar]
  • 20.Geneva: IFPMA; 1996. International Conference on Harmonization. Photo stability testing of new drug substance and products Q1B, International Conference on Harmonization. [Google Scholar]

Articles from Pharmaceutical Methods are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES